Nov 24, 2025, 07:58 AM by

Biocair, an established global leader in life science logistics, today announced the relocation of its Paris facility to a new, substantially larger premises strategically positioned within the Paris-Charles de Gaulle airport cargo zone.

Nov 24, 2025, 01:01 AM by User Not Found

Bio-IT World | Eli Lilly plans to open a new lab in Philadelphia; QIAGEN enters into a definitive agreement to fully acquire Parse Biosciences; Novartis announced plans to expand a flagship hub in North Carolina; and more.

Nov 21, 2025, 08:11 AM by

Nov 21, 2025, 07:58 AM by User Not Found

Bio-IT World | Ginkgo Datapoints has launched V-Ref293, a novel engineered cell line designated specifically as the reference standard for virtual cell research. Along with the cell line, the group is launching the Virtual Cell Pharmacology Initiative (VCPI), the first project under The Virtual Cell bio-AI community platform from Ginkgo Datapoints.

Nov 20, 2025, 08:22 AM by

Nov 19, 2025, 07:52 AM by

Nanopath, a point-of-care diagnostics company enabling high-quality molecular testing in minutes, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for the company's novel assay for the rapid detection of infection in patients with suspected, or at risk of, complicated urinary tract infections (UTIs).

Nov 19, 2025, 07:52 AM by

Accelerating medical device validation with digital solutions, risk-based methodology, and proven regulatory expertise.

Nov 19, 2025, 01:00 AM by User Not Found

Bio-IT World | Progress on women’s health, which was only truly recognized at the federal level when the Food and Drug Administration (FDA) asked for the inclusion of women in clinical trials in 1993, encountered a large obstacle earlier this year when the White House cut off a major funding initiative established by previous administrations intended to right the harms from decades of largely failing to include women in medical research. The move marks a succession of blind spot moments in the history of human research that have had damaging consequences for women.

Nov 18, 2025, 08:24 AM by

Zymo Research, a global leader in epigenetics and next-generation sequencing (NGS), has entered a strategic partnership with biomodal, an omics-based life sciences technology and analytics company. As part of biomodal’s certified provider network, Zymo Research’s NGS Services division is now authorized to deliver services using biomodal’s duet multiomics solution evoC and duet multiomics solution +modC, enabling researchers to access comprehensive genetic and epigenetic insights from a single DNA sample.

Nov 18, 2025, 01:01 AM by User Not Found

Bio-IT World | Last week, The Garvan Institute of Medical Research in Australia, the University of Tokyo in Japan, and 10x Genomics announced an initiative to create a comprehensive pan-cancer spatial atlas. The Asia-Pacific Spatial Translational Research Alliance (ASTRA), a consortium that fosters collaboration in spatial research across the Asia-Pacific region, will use 10x Genomics’ Xenium spatial platform to map how cancer and immune cells communicate across 2,000 tumor samples.

Nov 14, 2025, 08:54 AM by

BioGrad is spearheading efforts to place £10.5 million worth of donated PCR equipment by the end of 2025, with £6 million already delivered across the UK.

Nov 14, 2025, 01:00 AM by User Not Found

Bio-IT World | Early computational drug discovery relies on accurate predictions of binding affinity. If we can accurately predict the affinity of molecule designs, we can dramatically reduce the number of compounds that we need to synthesize and test when optimizing new drug candidates.

Nov 13, 2025, 08:15 AM by

IgniteData’s Archer platform will connect the site’s EHR system, Advarra’s eSource and EDC systems, and the sponsor’s EDC system of choice, ensuring compatibility between solutions from different vendors.

Nov 13, 2025, 08:15 AM by

Collaboration aims to equip users with complete NGS solution from sample to answer

Nov 13, 2025, 08:15 AM by

ThirdLaw Molecular, Inc. today announced its new name change, Ladder Bio Inc., reflecting the company’s mission to pioneer Spiroligomer™ therapeutics (“ladder-shaped peptide-like molecules”), a novel therapeutic modality for new medicines. The company name change follows the closing of a $5.5 million Series Seed financing led by Medical Excellence Capital, with participation from Hatch BioFund. The company also announced the appointment of Eric Heil as Chief Executive Officer and the election of David Scheer and Brian Halak, PhD to its Board of Directors.

Nov 12, 2025, 07:44 AM by

CluePoints, provider of leading statistical and AI-driven software solutions, has announced Sylviane de Viron, its Data and Knowledge Manager, has been appointed to the Applied Clinical Trials (ACT) editorial advisory board.

Nov 12, 2025, 01:00 AM by User Not Found

Bio-IT World | Though gender equity efforts in research have made strides, progress has plateaued. Roughly two-thirds of pivotal clinical trials leading to the U.S. Food and Drug Administration (FDA) drug approvals now include women at rates proportional to their disease burden, but the problem is fundamental issues in not considering female biology.

Nov 11, 2025, 08:11 AM by

* Ready-to-use solution, developed in collaboration with GenScript, offers rapid and reliable quantification of His-tagged proteins * Broadens Amperia’s applications across recombinant protein research, screening, and development * Abselion to showcase kit alongside Amperia platform at PEGS Europe in Lisbon, Portugal from 11–13 November

Nov 11, 2025, 08:11 AM by

MadeAi launched new capabilities in its MadeAi(TM) GenAI-powered platform for life science evidence synthesis and report generation - capabilities that expedite global value dossier (GVD) and Joint Clinical Assessment (JCA), and streamline literature review from protocol creation to regulatory-ready reporting.

Nov 11, 2025, 01:01 AM by User Not Found

Bio-IT World | Watchmaker Genomics has launched TAPS+, a next-generation technology that unites genetic and epigenetic readouts from the same DNA molecule. By capturing multiple biological dimensions in a single assay, TAPS+ delivers a richer, more comprehensive view of tumor biology.